Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years * Papillary thyroid cancer documented by * (a) Bethesda VI cytology, * (b) Bethesda III, IV, V, or VI cytology AND BRAF V600E mutation, or * (c) Bethesda V cytology AND high risk ultrasonographic features documented by either the ATA high suspicion or TIRADS 5 nodule characteristics To ensure the majority of cases will be eligible based on criteria (a) or (b), we will enroll ≤ 2 patients based on criteria (c). * Maximum diameter ≤ 13 mm * Declined active surveillance * The thyroid lesion must be primarily solid with ≤ 25% cystic compent * No US evidence of extrathyroidal extension through the thyroid capsule * No imaging evidence of lymph node metastasis * Preserved contralateral vocal cord function prior to PLA Exclusion Criteria: * Thyroid cancer that is non papillary thyroid cancer (PTC) * Thyroid lesion with \> 25% cystic component * Lesion with US evidence of extrathyroidal extension through the thyroid capsule * Clinical or ultrasonographic evidence of lymph node metastasis * Pregnancy